Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: The diagnosis of metastatic...

Question asked:

Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: The diagnosis of metastatic prostate carcinoma is incomplete and potentially misleading. This patient has TWO distinct primary cancers: Stage IV androgen receptor-positive parotid adenocarcinoma (PSMA IHC negative) with widespread bone metastases, AND a separate low-risk Gleason 3+3 prostate adenocarcinoma. The bone metastases are from the parotid primary, not the prostate cancer. Recommendation: URGENT: Correct [ID removed] to reflect primary diagnosis as Stage IV androgen receptor-positive parotid adenocarcinoma with bone metastases, with concurrent low-risk prostate cancer as secondary diagnosis. Confirm tissue diagnosis with repeat biopsy of bone lesion if any doubt remains. Refer to genetics for counseling on CDKN2A/NF1 mutations. Treatment should follow NCCN guidelines for salivary gland tumors (androgen receptor-positive subtype), NOT prostate cancer protocols. Tumor Board: Cutting Edge: The diagnosis is INCOMPLETE and potentially MISLEADING. This patient has TWO distinct primary cancers: (1) Stage IV androgen receptor-positive parotid adenocarcinoma with bone metastases (CDKN2A/NF1 mutations), and (2) separate low-risk Gleason 3+3 prostate cancer. The bone metastases are from the PAROTID cancer (PSMA IHC negative), NOT the prostate—yet imaging reports incorrectly attribute them to prostate carcinoma. Recommendation: URGENT: Correct the [ID removed] identify bone metastases as parotid-origin (not prostate). Obtain comprehensive molecular profiling (Foundation Medicine/Tempus) to identify additional actionable targets beyond CDKN2A/NF1. Refer to precision oncology tumor board for clinical trial matching—this AR+/PSMA-/CDKN2A-mutant/NF1-mutant profile has specific therapeutic opportunities being missed under a 'metastatic prostate cancer' framework. Tumor Board: Whole Person: The diagnosis is incomplete and potentially misleading. This patient has TWO distinct primary cancers: (1) Stage IV high-grade parotid adenocarcinoma with bone metastases (androgen receptor-positive, PSMA-negative), and (2) separate low-risk Gleason 3+3 prostate cancer. The bone metastases are from the parotid cancer, NOT the prostate cancer, which is a critical distinction for treatment planning. Recommendation: The primary diagnosis should be 'Stage IV metastatic parotid adenocarcinoma with osseous metastases' as the main concern, with 'concurrent low-risk prostate adenocarcinoma' as secondary. Confirm tissue diagnosis of at least one bone lesion via biopsy to definitively establish parotid origin, and ensure treatment targets the aggressive parotid cancer (not just ADT for prostate). Orthopedic evaluation for impending femoral fracture is urgent. Synthesize these perspectives. Respond in this exact JSON format: { "synthesis": "A 2-3 sentence synthesis of the key takeaways for the patient", "consensus": ["Point where all three agree", "Another point of agreement"], "divergence": ["Point where they disagree", "Another area of disagreement"] } Focus on actionable insights for the patient's next doctor conversation.